Company Profile
Personalis Stock Price, News & Analysis
- Ticker:
- PSNL
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
13.03 USD (-3.62%)
Close
Last updated: August 6, 2026
1.17B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, PSNL closed down 3.62% at $13.03. No new same-company headline was identified in the current news window.
Company overview
Precision-Oncology Genomics
Personalis develops genomic tests for cancer detection, monitoring and therapy development. Its platform uses highly sensitive sequencing and tumor-informed analysis to identify minimal residual disease.
NeXT Personal
NeXT Personal is a personalized circulating-tumor-DNA test designed to detect and track cancer recurrence from blood. Clinical use includes surveillance in lung and breast cancer. Personalis serves physicians through reimbursed clinical testing and pharmaceutical companies through translational research, clinical-trial and biomarker services.
Future catalysts
Personalis’s catalysts are MRD / oncology testing adoption, reimbursement, and whether the precision-genomics workflow keeps scaling. The next update matters if it shows the platform is becoming more recurring.
Recent news
- 01
Personalis Reports Second Quarter Results and Recent Highlights
Source: Personalis
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Personalis (PSNL)?
Personalis (PSNL) most recently closed at 13.03 USD, a -3.62% move versus the previous session.
What is the market cap of Personalis (PSNL)?
Personalis currently has a market capitalization of 1.17B USD on BioPharmSignal.
What does Personalis do?
Precision-Oncology Genomics Personalis develops genomic tests for cancer detection, monitoring and therapy development. Its platform uses highly sensitive sequencing and tumor-informed analysis to identify minimal residual disease. NeXT Personal NeXT Personal is a personalized circulating-tumor-DNA test designed to detect and track cancer recurrence from...
On which exchange is PSNL stock listed?
Personalis (PSNL) is associated with NASDAQ, United States, Biopharma.
What is Precision-Oncology?
Precision-Oncology Genomics Personalis develops genomic tests for cancer detection, monitoring and therapy development.
Which conditions is Personalis targeting with Precision-Oncology?
Personalis is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Personalis describe recent progress with Precision-Oncology?
Personalis’s catalysts are MRD / oncology testing adoption, reimbursement, and whether the precision-genomics workflow keeps scaling. The next update matters if it shows the platform is becoming more recurring.
What is Genomics?
Precision-Oncology Genomics Personalis develops genomic tests for cancer detection, monitoring and therapy development.